Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment

References

• Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–681.
   PubMed Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Capetti A, et al. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. HIV Med. 2019;20(2):164–168.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pântea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–2194.
   PubMed Web of Science ®Google Scholar
• Pan CQ, Afdhal NH, Ankoma-Sey V, et al. First-line therapies for hepatitis B in the United States: a 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun. 2022;6(8):1881–1894.
   PubMed Web of Science ®Google Scholar
• Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020;55(9):811–823.
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844.
   PubMed Web of Science ®Google Scholar
• Yang YM, Choi EJ. Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection. Ther Clin Risk Manag. 2017;13:1273–1285.
   PubMed Web of Science ®Google Scholar
• Zheng S, Liu L, Lu J, et al. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: a 2-year prospective study. Medicine . 2019;98(42):e17590.
   PubMed Web of Science ®Google Scholar
• Curran A, Rull A, Navarro J, et al. Lipidomics reveals reduced inflammatory lipid species and storage lipids after switching from EFV/FTC/TDF to RPV/FTC/TDF: a randomized open-label trial. J Clin Med. 2020;9(5):1246.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Aids. 2019;33(9):1455–1465.
   PubMed Web of Science ®Google Scholar
• Moafi M, Assadi F, Heshmat R, et al. Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study. World J Pediatr. 2019;15(5):471–475.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Zoulim F, Hézode C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;61(10):3072–3083.
   PubMed Web of Science ®Google Scholar
• Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/TDF in treatment-© adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind. Clin Infect Dis. 2021;73(1):33–42.
   PubMed Web of Science ®Google Scholar
• Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34(15):2259–2268.
   PubMed Web of Science ®Google Scholar
• Squillace N, Ricci E, Menzaghi B, et al. The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile. Drug Des Devel Ther. 2020;14:5515–5520.
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Berger F, Arenas-Pinto A, et al. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387–2391.
   PubMed Web of Science ®Google Scholar
• Yang J, Chen J, Ji Y, et al. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients. Int J Infect Dis. 2019;83:64–71.
   PubMed Web of Science ®Google Scholar
• Birken SA, Powell BJ, Presseau J, et al. Combined use of the consolidated framework for implementation research (CFIR) and the theoretical domains framework (TDF): a systematic review. Implement Sci. 2017;12(1):2.
   PubMedGoogle Scholar
• Liu SQ, Zhang XJ, Xue Y, et al. Dynamic changes of estimated glomerular filtration rate are conversely related to triglyceride in non-overweight patients. World J Clin Cases. 2022;10(31):11371–11380.
   PubMed Web of Science ®Google Scholar
• Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;(99):S87–S93.
   Google Scholar
• Weldegiorgis M, Woodward M. Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. BMC Nephrol. 2022;23(1):312.
   PubMed Web of Science ®Google Scholar
• Kim J, Shin SJ, Kim YS, et al. Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults. Cardiovasc Diabetol. 2021;20(1):183.
   PubMed Web of Science ®Google Scholar
• Tsuruya K, Yoshida H, Nagata M, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. 2014;233(1):260–267.
   PubMed Web of Science ®Google Scholar
• Kim J, Bae YJ, Shin SJ, et al. The ratio of triglycerides to high-density lipoprotein cholesterol is associated with the risk of chronic kidney disease in Korean men. Lipids. 2021;56(5):475–483.
   PubMed Web of Science ®Google Scholar